California State Teachers Retirement System Grows Position in Hologic, Inc. (NASDAQ:HOLX)

California State Teachers Retirement System grew its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 5.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 452,817 shares of the medical equipment provider's stock after buying an additional 24,220 shares during the period. California State Teachers Retirement System owned 0.20% of Hologic worth $32,644,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of HOLX. Principal Financial Group Inc. lifted its holdings in shares of Hologic by 0.6% in the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock valued at $19,547,000 after purchasing an additional 1,606 shares during the last quarter. Groupama Asset Managment lifted its holdings in shares of Hologic by 63.4% in the 4th quarter. Groupama Asset Managment now owns 54,214 shares of the medical equipment provider's stock valued at $3,918,000 after purchasing an additional 21,037 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Hologic in the 4th quarter valued at about $4,215,000. Signaturefd LLC lifted its holdings in shares of Hologic by 34.5% in the 4th quarter. Signaturefd LLC now owns 2,940 shares of the medical equipment provider's stock valued at $212,000 after purchasing an additional 754 shares during the last quarter. Finally, Brevan Howard Capital Management LP lifted its holdings in shares of Hologic by 85.5% in the 4th quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider's stock valued at $1,401,000 after purchasing an additional 8,960 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several research reports. Leerink Partnrs downgraded Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Citigroup reduced their price objective on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Finally, Evercore ISI reduced their price objective on Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research note on Friday, May 2nd. Twelve research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $77.42.

Hologic Stock Performance

NASDAQ HOLX traded down $0.16 on Monday, hitting $62.01. 2,584,438 shares of the company's stock were exchanged, compared to its average volume of 2,269,873. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm's 50-day moving average price is $58.15 and its two-hundred day moving average price is $65.69. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67. The firm has a market cap of $13.82 billion, a price-to-earnings ratio of 19.56, a P/E/G ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. During the same quarter in the previous year, the firm posted $1.03 EPS. The firm's quarterly revenue was down 1.2% on a year-over-year basis. On average, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling

In other news, Director Martin D. Madaus purchased 5,445 shares of the stock in a transaction that occurred on Wednesday, May 7th. The shares were acquired at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the acquisition, the director now directly owns 5,445 shares in the company, valued at approximately $300,781.80. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.88% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.